

# Out-patient management of missed miscarriage: a randomised trial of medical vs medical/minimally invasive management using transcervical amnion rupture

<b>Submission date</b> 30/09/2004	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
<b>Registration date</b> 30/09/2004	<b>Overall study status</b> Completed	<input type="checkbox"/> Protocol
<b>Last Edited</b> 02/06/2017	<b>Condition category</b> Pregnancy and Childbirth	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

## Plain English Summary

Not provided at time of registration

## Contact information

### Type(s)

Scientific

### Contact name

Mr Kevin Harrington

### Contact details

Fetal Medicine Unit  
Homerton University Hospital NHS Trust  
Homerton Row  
London  
United Kingdom  
E9 6SR  
+44 (0)20 8510 7544  
kevin.harrington@virgin.net

## Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

## Secondary identifying numbers

N0024125765

# Study information

## Scientific Title

Out-patient management of missed miscarriage: a randomised trial of medical vs medical /minimally invasive management using transcervical amnion rupture

## Study hypothesis

The aim of this study is to compare vaginal misoprostol alone against transcervical amniotic puncture followed by vaginal misoprostol in the outpatient management of missed miscarriage.

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Not provided at time of registration

## Study design

Randomised controlled trial

## Primary study design

Interventional

## Secondary study design

Randomised controlled trial

## Study setting(s)

Hospital

## Study type(s)

Treatment

## Participant information sheet

## Condition

Pregnancy and Childbirth: Miscarriage

## Interventions

Vaginal misoprostol (800 mcg) alone against transcervical amniotic puncture followed by vaginal misoprostol (800 mcg)

## Intervention Type

Drug

## Phase

Not Applicable

## Drug/device/biological/vaccine name(s)

Misoprostol

**Primary outcome measure**

1. Rate of complete expulsion within 24 hr and 48 hr and time to complete expulsion
2. Number of misoprostol doses required; number requiring ERPC
3. Analgesia requirements
4. Infection rate
5. Haemoglobin change/need for blood transfusion
6. Patient satisfaction via questionnaire

**Secondary outcome measures**

Not provided at time of registration

**Overall study start date**

01/04/2003

**Overall study end date**

31/12/2003

## **Eligibility**

**Participant inclusion criteria**

20-40 patients with diagnosis of missed miscarriages

**Participant type(s)**

Patient

**Age group**

Adult

**Sex**

Female

**Target number of participants**

40

**Participant exclusion criteria**

Not provided at time of registration

**Recruitment start date**

01/04/2003

**Recruitment end date**

31/12/2003

## **Locations**

**Countries of recruitment**

England

United Kingdom

**Study participating centre**  
**Fetal Medicine Unit**  
London  
United Kingdom  
E9 6SR

## Sponsor information

**Organisation**  
Department of Health

**Sponsor details**  
Richmond House  
79 Whitehall  
London  
United Kingdom  
SW1A 2NL

**Sponsor type**  
Government

**Website**  
<http://www.dh.gov.uk/Home/fs/en>

## Funder(s)

**Funder type**  
Government

**Funder Name**  
Homerton University Hospital NHS Trust (UK)

## Results and Publications

**Publication and dissemination plan**  
Not provided at time of registration

**Intention to publish date**

## **Individual participant data (IPD) sharing plan**

### **IPD sharing plan summary**

Not provided at time of registration